Federated Hermes Inc. Sells 755,840 Shares of Sanofi (NASDAQ:SNY)

Federated Hermes Inc. cut its position in Sanofi (NASDAQ:SNY) by 30.6% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 1,717,320 shares of the company’s stock after selling 755,840 shares during the period. Federated Hermes Inc.’s holdings in Sanofi were worth $85,402,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. SRS Capital Advisors Inc. raised its stake in shares of Sanofi by 289.1% during the 1st quarter. SRS Capital Advisors Inc. now owns 463 shares of the company’s stock valued at $25,000 after purchasing an additional 344 shares during the period. Householder Group Estate & Retirement Specialist LLC bought a new stake in shares of Sanofi during the 3rd quarter valued at $26,000. Fairfield Bush & CO. bought a new stake in shares of Sanofi during the 1st quarter valued at $26,000. Rise Advisors LLC grew its position in Sanofi by 98.4% during the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock worth $25,000 after buying an additional 251 shares in the last quarter. Finally, Salem Investment Counselors Inc. purchased a new position in Sanofi during the fourth quarter worth about $27,000. 10.04% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

SNY has been the subject of several recent analyst reports. TheStreet cut Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. Morgan Stanley initiated coverage on Sanofi in a research report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 target price for the company. Finally, StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Sanofi currently has a consensus rating of “Hold” and an average target price of $55.00.

Sanofi Trading Down 1.6 %

NASDAQ SNY opened at $45.39 on Friday. Sanofi has a 1-year low of $42.63 and a 1-year high of $57.82. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The stock has a 50-day moving average of $47.52 and a 200-day moving average of $48.67. The firm has a market cap of $114.82 billion, a PE ratio of 19.23, a price-to-earnings-growth ratio of 1.72 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). Sanofi had a net margin of 12.56% and a return on equity of 27.47%. The company had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $13.02 billion. As a group, sell-side analysts forecast that Sanofi will post 4.15 EPS for the current year.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be given a dividend of $1.478 per share. This is a positive change from Sanofi’s previous annual dividend of $1.38. The ex-dividend date is Thursday, May 9th. This represents a yield of 2.98%. Sanofi’s dividend payout ratio is presently 58.47%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.